Multiple Sclerosis Relapses and Severe Disability
Published : 2009-11-05
Author : American Academy of Neurology
Synopsis* : People with multiple sclerosis who have relapses within five years of onset have more severe disability in the short term.
Main DigestPeople with multiple sclerosis (MS) who have relapses within the first five years of onset appear to have more severe disability in the short term compared to people who do not have an early relapse, according to a new study published in the November 4, 2009, issue of Neurology, the medical journal of the American Academy of Neurology.
The study is one of the first to examine how MS relapses affect people during different time periods of the disease.
Research shows that 85 percent of people with MS begin by having the relapsing-remitting form of the disease and the majority of these people later develop secondary progressive MS. A relapse is defined in the study as worsening of neurological symptoms for more than 24 hours, without a fever or infection. Because relapse-related symptoms often improve within a few weeks, it's been unclear how much disability comes from relapses, and how much from progression.
For the study, scientists reviewed the medical records of 2,477 people with MS who experienced relapses in British Columbia, Canada. The study looked at whether the participants had disability severe enough to require the use of a cane for walking and whether this was related to relapses occurring within five years, five to 10 years, or more than 10 years after onset of symptoms. The participants were followed for an average of 20 years. During that time, the group experienced 11,722 relapses.
Scientists found that people who had a relapse within five years of disease onset were at a 48 percent higher hazard (a measure of relative risk) of needing a cane to walk within five years of disease onset than those who did not have an early relapse. Importantly, the impact of the early relapse lessened over time. Those with early relapse who did not need a cane after five years were at only a 10 percent higher hazard (a measure of relative risk) of needing one 10 years after disease onset than those without early relapses.
"Our findings may represent an important message to people diagnosed with MS today. Those who have a history of relapses could potentially be offered reassurance that as time goes on, these relapses will have a diminishing effect on their everyday lives," said study author Helen Tremlett, PhD, with the University of British Columbia in Vancouver. "In addition, our study calls upon the need for new medications that target axonal degeneration, which is suspected of causing permanent disability, especially for people who have had MS for many years or who are older at diagnosis."
The impact of relapses that occurred later, either at five to 10 or more than 10 years after the start of the disease, also waned over time and became insignificant after long-term follow up. Relapses in people under 25 had a longer impact on disability compared to those over 35 years.
"There may be a longer window of opportunity for treating younger people with MS right away, changing the course of progression later on," Tremlett said.
The study was supported by the U. S. National MS Society.
The American Academy of Neurology, an association of more than 21,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care through education and research. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease, and multiple sclerosis.
For more information about the American Academy of Neurology, visit www.aan.com or www.thebrainmatters.org
You're reading Disabled World. Be sure to check out our homepage for further informative disability news, reviews, disability sports events, exclusive stories and how-tos. You can also find us on Twitter, Facebook, and LinkedIn.
Related Multiple Sclerosis Documents
- 1 - New Multiple Sclerosis Treatment Clinical Trial Begins Enrollment : Clinical trial of Autologous Hematopoietic Stem Cell Transplantation versus Best Available Therapy for Multiple Sclerosis (BEAT-MS) begins enrollment.
- 2 - Stigma Increases Risk of Depression for People with Multiple Sclerosis : Those with MS who feel stigmatized are more likely to have depression, having a support system of friends and family and a sense of autonomy may help reduce the harmful effects of stigma..
- 3 - $7M MS Progression Cohort to Research Multiple Sclerosis in Canada : Research proposals will invite researchers to establish a Canadian cohort of people living with MS to study progression in the disease.
- 4 - How Can We Predict Whose Multiple Sclerosis Will Worsen? : Multiple Sclerosis study brings us closer to understanding which older adults with MS may be at higher risk of getting worse.
- 5 - Cladribine Significantly Reduces Brain Atrophy in Patients with Multiple Sclerosis : Phase III CLARITY study data revealed significant reduction in brain atrophy in patients on short course of investigational Cladribine Tablets over two years.
*Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information. Please report outdated or inaccurate information to us.
Journal: Disabled World. Language: English (U.S.). Author: American Academy of Neurology. Electronic Publication Date: 2009-11-05. Title: Multiple Sclerosis Relapses and Severe Disability, Source: <a href=https://www.disabled-world.com/health/autoimmunediseases/ms/ms-relapses.php>Multiple Sclerosis Relapses and Severe Disability</a>. Retrieved 2021-05-07, from https://www.disabled-world.com/health/autoimmunediseases/ms/ms-relapses.php - Reference: DW#263-2681.